NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...

Masimo Corp MASI recently announced that its SedLine brain function monitor has been selected by Penn Highlands DuBois, a health centre with one of the best hospital safety scores (according to ...

The FDA has FDA cleared Masimo Corp's (NASDAQ: MASI) SedLine brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor. SedLine helps clinicians monitor ...

Masimo has made a name for itself as a prolific purveyor of noninvasive patient monitoring technologies, from the SET pulse oximeter to the recently CE-marked Rainbow SuperSensor, which continuously ...

Next Generation SedLine Now Available for Use on Patients 1-18 Years Old in CE Mark Countries NEUCHATEL, Switzerland — Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® ...